A number of firms have modified their ratings and price targets on shares of Iovance Biotherapeutics (NASDAQ: IOVA) recently:
- 8/20/2026 – Iovance Biotherapeutics had its price target raised by UBS Group AG from $4.00 to $7.00. They now have a “neutral” rating on the stock.
- 8/18/2026 – Iovance Biotherapeutics had its price target raised by Mizuho from $10.00 to $11.00. They now have an “outperform” rating on the stock.
- 8/7/2026 – Iovance Biotherapeutics was given a new $6.00 price target by Robert W. Baird.
- 8/7/2026 – Iovance Biotherapeutics had its “outperform” rating reaffirmed by Citigroup Inc..
- 8/7/2026 – Iovance Biotherapeutics had its price target raised by Barclays PLC from $11.00 to $13.00. They now have an “overweight” rating on the stock.
- 8/7/2026 – Iovance Biotherapeutics had its price target raised by Citizens Jmp from $5.00 to $8.00. They now have a “market outperform” rating on the stock.
- 7/2/2026 – Iovance Biotherapeutics had its “sell (d-)” rating reaffirmed by Weiss Ratings.
Iovance Biotherapeutics, Inc is a clinical‐stage biotechnology company specializing in the development and commercialization of tumor‐infiltrating lymphocyte (TIL) immunotherapies for the treatment of solid tumors. The company’s lead product candidate, lifileucel (formerly LN‐144), is an autologous TIL therapy in late‐stage clinical development for patients with advanced melanoma. Iovance’s pipeline also includes next‐generation TIL programs such as LN‐145 for cervical and other human papillomavirus (HPV)‐related cancers, as well as exploratory studies in head and neck, non‐small cell lung, gastric and other solid tumor indications.
Iovance’s TIL platform harnesses a patient’s own immune system by isolating, expanding and reinfusing tumor‐reactive lymphocytes.
Featured Stories
- Five stocks we like better than Iovance Biotherapeutics
- 3 Energy Stocks Raising Dividends as the Sector Surges
- 5 Reasons the S&P 500 Could Keep Rallying Through Year-End
- Walmart’s Post-Earnings Drop Could Be a Buying Opportunity
- The Trade Desk’s Earnings Miss Raises a Bigger Question About Its AI Future
Receive News & Ratings for Iovance Biotherapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iovance Biotherapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.
